On 2026-11-13, the China National Intellectual Property Administration published cases jointly selected by three authorities from comprehensive intellectual property finance ecosystem pilots. An official case included a buyer-credit product for intellectual property acquisitions. It concerned consolidating rights associated with advanced medical equipment: key technologies had been held by different partners, and financing supported the acquisition of the relevant intellectual property. This is a published example of a financing approach, not evidence that every science and technology company can apply for an equivalent product.

On 2026-11-12, Mirendil announced a $1B Series A. Its company announcement presented broader access to frontier artificial intelligence research and development as its objective. This overseas financing is background only: it does not establish that funding for technology acquisitions is available to domestic companies, and its announced amount cannot be used to estimate their budgets. Youdu Capital serves domestic financing for Chinese technology companies and does not provide cross-border financial services. The following is general mechanism analysis, not a judgment about the arrangements of the companies mentioned above.

Suppose a domestic equipment company plans to obtain several technology rights that must be used together, each controlled by a different partner. Current quotations can be added together, but whether the product can enter production as planned depends on whether the complete set of rights is usable. If a missing component would require a different technical route, the funding-use plan cannot simply accumulate the transactions already negotiated. It must also identify payments that depend on other transactions completing, and payments that would produce no standalone operating value once made.

The first causal link comes from technological complementarity. Modules that can be sold independently may be funded and validated individually, whereas complementary technologies may yield a product only after the combination is complete. Acquiring some rights then increases assets without necessarily increasing delivery capability. If a budget treats each acquisition as an independent milestone, more recorded progress can make the final unresolved condition easier to overlook. The funding requirement may consequently be misrepresented as ordinary capacity expansion.

The second effect is that earlier commitments can change the company's position in later negotiations. Once equipment, staffing and customer plans have been organized around a technical route, switching routes may become more expensive. Remaining partners need not change their quotations for the company's tolerance for delay to have shortened. The exposure therefore includes not only a right costing more than expected, but also continuing expenditure while waiting and whether previously available alternatives remain practical. This analysis does not presume misconduct by any partner.

Fundraising materials can start with a table connecting technologies to products. Technical staff, business staff and professional advisers can check which functions each right supports, which functions must coexist and where lawful alternatives already exist. The connections should be supported by existing documents or experimental records, rather than conclusions added to make a diagram appear complete. Unconfirmed points should remain open, with an explanation of the materials needed to assess their effect on funding uses.

The next step is to turn the amount schedule into a schedule of conditions. Expenditure that creates standalone value can follow its own progress. Expenditure dependent on the complete set of rights should separately show waiting costs and what remains reversible if the combination is incomplete. Different scenarios can use the same verified quotations, changing the completion sequence before comparing the lowest cash position. This reveals the gap that needs coverage without inventing precise probabilities of success or price increases.

The schedule of conditions should also identify the earliest point when the complete set of rights can be used together. Completing the formalities for one component does not make the product immediately ready for sale, so the budget should not bring forward sales receipts while necessary conditions remain unmet. If the waiting period adds only maintenance expenditure, that cash consumption should be shown separately. The schedule should also state who will update the assessment when subsequent conditions change, so that acquisition progress and assumptions about cash receipts remain aligned.

Payment order should also match these conditions. Paying less upfront is not automatically better: some early work generates essential evidence, while other work merely increases dependence on an unfinished combination. Founders should explain what information, capability or enforceable rights each payment obtains before deciding whether to start the next expenditure. Arrangements involving instalments, conditions precedent, licensing or exit should be discussed with appropriately qualified professional institutions. This article does not provide specific contractual provisions.

Over the next 3–6 months, a company negotiating several complementary technologies in parallel can select one product and record the delivery functions genuinely added after each right is confirmed. If the combination remains incomplete while waiting costs continue, it should reassess alternative routes and the scope of any pause before updating funding uses. If some modules can be commercialized independently, their budgets can be listed separately with the corresponding evidence. Both paths depend on actual technical and transaction progress and should not be presented in advance as certain achievements.

The method ultimately asks what complete capability this round can create, and what must still be paid before that capability exists. Recasting an acquisition list as completion conditions allows capital providers to discuss identifiable funding exposures instead of merely seeing a growing asset list. Youdu Capital's domestic financing services do not replace technical, ownership or credit assessments. This article offers general analysis based on public sources, promises no financing or operating outcome, and is not specific investment, legal or tax advice.

Sources 国家金融监督管理总局 国家知识产权局 国家版权局联合发布知识产权金融生态综合试点典型案例 / NFRA, CNIPA and NCAC jointly release typical cases from integrated pilots for the intellectual property finance ecosystem (2026-11-13) https://www.cnipa.gov.cn/art/2026/11/13/art_75_209094.html Mirendil前沿AI研发工具公司A轮融资公告 / Mirendil Series A funding announcement (2026-11-12) https://mirendil.com/news/series-a/

Content note: This article was drafted with AI assistance and reviewed through an independent AI process, using the listed public sources. It contains no original interviews, and no first-hand testing of the products, services or methods discussed was conducted. Checking public sources is not a field investigation or first-hand experience.